Mogo Moringa LLC Recalls Two Capsule Lots After FDA Coordination Despite Negative Lab Results

A precautionary recall executed without confirmed contamination offers a sharper compliance lesson than most: Mogo Moringa LLC is pulling two lots of its Mogo Moringa Oleifera Capsules following discussions with FDA, even after independent third-party laboratory testing returned no detection of Salmonella on retained samples from the affected lots.

The recall covers Lot 15525AA (exp. 06/2027) and Lot 00926AA (exp. 01/2028), both packaged in white plastic bottles and distributed exclusively through the company's official online channels. No other lots or products are included. The Saint Louis, Missouri-based company states that no third-party sellers are authorized to distribute its products, a distribution-control posture that will factor into any traceability assessment during FDA's ongoing evaluation.

For QA directors, the compliance read centers on risk-based decision-making under supplement GMP requirements. The company proceeded with a voluntary recall not because analytical data confirmed a hazard, but because FDA coordination and precautionary risk logic drove the action. That sequence, agency dialogue preceding a recall despite negative results, reflects the kind of documented, defensible decision trail that regulators expect to see in a robust quality system aligned with 21 CFR Part 111, the current Good Manufacturing Practice regulation governing dietary supplements.

The company has indicated it is strengthening internal quality controls and testing procedures as part of its corrective response. Whether those changes constitute a formal CAPA or a broader process review has not been disclosed, but the public commitment creates a documented baseline that FDA investigators will likely reference in any follow-up inspection.

Consumers holding product from either affected lot are advised not to use it; the company's recall information page provides return and contact guidance.

The measurable outcome to track is FDA's conclusion of its ongoing evaluation, which will determine whether the precautionary action was sufficient or whether additional corrective steps are required across Mogo Moringa LLC's quality system.

Source: U.S. Food and Drug Administration, Recalls, Market Withdrawals & Safety Alerts, published May 26, 2026; company announcement dated May 25, 2026.